Zastaprazan
ApprovedSmall molecule
Zastaprazan is one of 86 small molecule programs targeting Acute Myocardial Infarction. It is currently in Approved.
3
Indications
3
Total Trials
3
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
216 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaPhase 3
Adenocard
AstellasPhase 3
Byetta
AstraZenecaPhase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
Rayaldee
OOrganon and Co
Phase 3
Reopro
Boehringer IngelheimPhase 3
Glucophage
EMD SeronoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Jardiance
Boehringer IngelheimPhase 3
Xarelto
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Percutaneous Coronary Intervention1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zastaprazan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- YYonsei University